123 related articles for article (PubMed ID: 35616188)
21. Cancer stem cells enrichment with surface markers CD271 and CD44 in human head and neck squamous cell carcinomas.
Elkashty OA; Abu Elghanam G; Su X; Liu Y; Chauvin PJ; Tran SD
Carcinogenesis; 2020 Jun; 41(4):458-466. PubMed ID: 31742606
[TBL] [Abstract][Full Text] [Related]
22. CD44 Interacts with HIF-2α to Modulate the Hypoxic Phenotype of Perinecrotic and Perivascular Glioma Cells.
Johansson E; Grassi ES; Pantazopoulou V; Tong B; Lindgren D; Berg TJ; Pietras EJ; Axelson H; Pietras A
Cell Rep; 2017 Aug; 20(7):1641-1653. PubMed ID: 28813675
[TBL] [Abstract][Full Text] [Related]
23. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties.
Leung EL; Fiscus RR; Tung JW; Tin VP; Cheng LC; Sihoe AD; Fink LM; Ma Y; Wong MP
PLoS One; 2010 Nov; 5(11):e14062. PubMed ID: 21124918
[TBL] [Abstract][Full Text] [Related]
24. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
Geng S; Guo Y; Wang Q; Li L; Wang J
Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
[TBL] [Abstract][Full Text] [Related]
25. LncRNA DGCR5 contributes to CSC-like properties via modulating miR-330-5p/CD44 in NSCLC.
Wang R; Dong HX; Zeng J; Pan J; Jin XY
J Cell Physiol; 2018 Sep; 233(9):7447-7456. PubMed ID: 29663359
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N
Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640
[TBL] [Abstract][Full Text] [Related]
27. Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells.
Gomez KE; Wu F; Keysar SB; Morton JJ; Miller B; Chimed TS; Le PN; Nieto C; Chowdhury FN; Tyagi A; Lyons TR; Young CD; Zhou H; Somerset HL; Wang XJ; Jimeno A
Cancer Res; 2020 Oct; 80(19):4185-4198. PubMed ID: 32816856
[TBL] [Abstract][Full Text] [Related]
28. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
Bourguignon LY; Wong G; Earle C; Chen L
J Biol Chem; 2012 Sep; 287(39):32800-24. PubMed ID: 22847005
[TBL] [Abstract][Full Text] [Related]
29. NEAT1 is Required for the Expression of the Liver Cancer Stem Cell Marker CD44.
Koyama S; Tsuchiya H; Amisaki M; Sakaguchi H; Honjo S; Fujiwara Y; Shiota G
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168951
[TBL] [Abstract][Full Text] [Related]
30. CD44+ cancer stem-like cells in EBV-associated nasopharyngeal carcinoma.
Lun SW; Cheung ST; Cheung PF; To KF; Woo JK; Choy KW; Chow C; Cheung CC; Chung GT; Cheng AS; Ko CW; Tsao SW; Busson P; Ng MH; Lo KW
PLoS One; 2012; 7(12):e52426. PubMed ID: 23285037
[TBL] [Abstract][Full Text] [Related]
31. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity.
Cortes-Dericks L; Froment L; Boesch R; Schmid RA; Karoubi G
BMC Cancer; 2014 Apr; 14():304. PubMed ID: 24884875
[TBL] [Abstract][Full Text] [Related]
33. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers.
Olsson E; Honeth G; Bendahl PO; Saal LH; Gruvberger-Saal S; Ringnér M; Vallon-Christersson J; Jönsson G; Holm K; Lövgren K; Fernö M; Grabau D; Borg A; Hegardt C
BMC Cancer; 2011 Sep; 11():418. PubMed ID: 21957977
[TBL] [Abstract][Full Text] [Related]
34. EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells.
Jiang P; Xu C; Chen L; Chen A; Wu X; Zhou M; Haq IU; Mariyam Z; Feng Q
Mol Carcinog; 2018 Dec; 57(12):1835-1844. PubMed ID: 30182373
[TBL] [Abstract][Full Text] [Related]
35. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells.
Wan S; Zhao E; Kryczek I; Vatan L; Sadovskaya A; Ludema G; Simeone DM; Zou W; Welling TH
Gastroenterology; 2014 Dec; 147(6):1393-404. PubMed ID: 25181692
[TBL] [Abstract][Full Text] [Related]
36. The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.
Mohamed SY; Kaf RM; Ahmed MM; Elwan A; Ashour HR; Ibrahim A
J Gastrointest Cancer; 2019 Dec; 50(4):824-837. PubMed ID: 30136202
[TBL] [Abstract][Full Text] [Related]
37. SMURF1 silencing diminishes a CD44-high cancer stem cell-like population in head and neck squamous cell carcinoma.
Khammanivong A; Gopalakrishnan R; Dickerson EB
Mol Cancer; 2014 Dec; 13():260. PubMed ID: 25471937
[TBL] [Abstract][Full Text] [Related]
38. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth.
Pietras A; Katz AM; Ekström EJ; Wee B; Halliday JJ; Pitter KL; Werbeck JL; Amankulor NM; Huse JT; Holland EC
Cell Stem Cell; 2014 Mar; 14(3):357-69. PubMed ID: 24607407
[TBL] [Abstract][Full Text] [Related]
39. All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells.
Yao W; Wang L; Huang H; Li X; Wang P; Mi K; Cheng J; Liu H; Gu C; Huang L; Huang J
BMC Cancer; 2020 Apr; 20(1):315. PubMed ID: 32293355
[TBL] [Abstract][Full Text] [Related]
40. Characterization of CD44-positive Cancer Stem-like Cells in COLO 201 Cells.
Okuyama H; Nogami W; Sato Y; Yoshida H; Tona Y; Tanaka Y
Anticancer Res; 2020 Jan; 40(1):169-176. PubMed ID: 31892565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
